# Comparison of ondansetron and tropisetron in preventing postoperative nausea and vomiting

A meta-analysis of randomized controlled trials

Rui Wang, MS, Xuesong Song, MD, PhD, Yan Chen, MD, Na Wang, MD, PhD, Jinguo Wang, MD, PhD.

## ABSTRACT

الأهداف : لمقارنة فعالية عقار أوندانسيترون وعقار تروبيسيترون للوقاية من الغثيان والقيء بعد الجراحة ( PONV ) .

المنهجية : أجرينا بحث في محركات البحث للدراسات السابقة لتحديد البحوث التي تقارن كفاءة عقار أوندانسيترون مع عقار التروبيسيترون في منع PONV . اشتملت التجارب المعشاة ذات الشواهد فقط التي تم تحديثها حتى يناير 2021م .

النتائج : اشتمل التحليل النهائي على 14 دراسة مجموع 1705 مريضًا وأشار إلى أن عقار أوندانسيترون كان أقل فعالية بنسبة 39% من عقار تروبيسيترون في منع القيء بعد الجراحة مع ارتفاع معدل حدوث الدوخة. ومع ذلك، لم يتم الكشف عن اختلاف كبير بين عقار أوندانسيترون و عقار تروبيسيترون في PONV والغثيان بعد الجراحة والعلاج المضاد للقيء والصداع.

الخلاصة: يتفوق عقار تروبيسترون على عقار أوندانسيترون في منع القيء بعد الجراحة.

**Objectives:** To compare the efficacy of prophylactic ondansetron and tropisetron for postoperative nausea and vomiting (PONV).

**Methods:** A literature search was performed to identify studies that compare the efficiency of ondansetron with that of tropisetron in preventing PONV. Only randomized controlled trials updated to January, 2021 were included.

**Results:** The final pooled analysis included 14 studies totaling 1705 patients and indicated that ondansetron was 39% less effective than tropisetron in preventing postoperative vomiting with a higher incidence of dizziness. However, no significant difference was detected between ondansetron and tropisetron in PONV, postoperative nausea, antiemetic treatment, and headache.

**Conclusions:** Tropisetron is superior to ondansetron in preventing postoperative vomiting. PROSPERO No: CRD42021237368

Keywords: meta-analysis, ondansetron, tropisetron, postoperative, antiemetic

#### Saudi Med J 2021; Vol. 42 (7): 707-713 doi: 10.15537/smj.2021.42.7.20210135

From the Department of Computer Network (Wang R), Technology School, Jilin Business and Technology College, Changchun, Jilin; from the Department of Anesthesiology (Song, Chen, Wang N); and from the Department of Urology (Wang J), The First Hospital of Jilin University, Changchun, China.

Received 18th March 2021. Accepted 31st May 2021.

Address correspondence and reprint request to: Dr. Jinguo Wang, Department of Urology, The First Hospital of Jilin University, Changchun, China. E-mail: jinguo@jlu.edu.cn ORCID ID: http://orcid.org/0000-0001-9794-9789

**P**ostoperative nausea and vomiting (PONV) is a distressing side effect after anesthesia,<sup>1</sup> because it may cause some adverse effects such as deprivation of body fluids, electrolyte imbalance, delayed recovery, aspiration pneumonia, and decreased satisfaction of patients' after surgery.<sup>2</sup>

Prophylactic administration of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists has been utilized as an effective method for preventing PONV. Comparative studies between different 5-HT3 antagonists for preventing PONV failed to show a clear advantage of a specific 5-HT3 antagonist.<sup>3</sup>

This meta-analysis was designed to determine the effect of two 5-HT3 receptor antagonists with different half-lives in preventing PONV, that is, the short-acting ondansetron versus the relatively long-acting tropisetron.

**Methods.** Two investigators (NW, RW) identified the eligible studies by searching PubMed, Web of Science, Cochrane Library, and Google Scholar, using "prevention," "nausea," "vomiting," "ondansetron," and

**Disclosure**. Authors have no conflict of interests, and the work was not supported or funded by any drug company.



"tropisetron" as search terms updated to January, 2021. Potential randomized controlled trials (RCTs) were identified by a systematic search of reference lists from related articles.

Inclusion criteria were: a RCT study; patients should have undergone operation; records of PONV-data; ondansetron or tropisetron administered prophylactically; and ondansetron and tropisetron comparison. On the other hand, none-english articles, animal studies, children studies, and published abstracts, meeting papers and letters were excluded.

The quality of the RCTs was separately evaluated by 2 investigators (JW, XS) utilizing the Cochrane Collaboration guidelines and Jadad improvement score.<sup>4,5</sup> Studies with Jadad improvement score of less than 4 were excluded.

Two independent investigators (YC, RW) extracted relevant data from the included studies. The primary outcome was PONV, while additional outcomes included the requirement of antiemetic treatment and the related complications. Any disagreement was solved by a third investigator.

*Statistical analysis.* Statistical calculations were conducted using Revman 5.3 (Cochrane Collaboration). The outcome was displayed as odds ratio (OR) with 95% confidence interval (CI). I<sup>2</sup> value was utilized to evaluate heterogeneity. If I<sup>2</sup> ≤50%, a fixed-effect model was peformed. Funnel plot and Egger test were utilized to assess publication bias. Statistical significance was p<0.05.

**Results.** The literature search identified 68 articles initially. After reading the abstracts, 42 studies were excluded. Of the 26 remaining studies, 14 articles were included in this meta-analysis after reviewing the full manuscript (**Figure 1**).<sup>6-19</sup> The characteristics of the 14 articles involving 1705 patients are summarized in **Table 1**. An overview of the risk of bias was shown in **Figure 2**.




Figure 1 - Flow diagram of literature search.

### **Table 1** - Characteristics of the included studies.

Author/ year	Dosage	Jadad improvement score	Sample size O/T	Patient characteristics/ surgical setting	Administration time	PONV measurement tool	Observing time (hours)	Outcomes measures
Aydin et al <sup>6</sup> 2019	Ondansetron 8 mg; Tropisetron 5 mg	7	55/55	18-65 years, ASA: I-II; Middle ear surgery; General anesthesia	During skin closure	Visual analog score 0-3	48	a, b, c, d, e
Jokela et al <sup>7</sup> 2002	Ondansetron 16 mg; Tropisetron 5 mg	7	60/60	O: 51±13 years; T: 49±14 years; ASA: I-III; female; Thyroid or parathyroid surgery; General anesthesia	Orally 1 hour before the operation	Yes or no	24	a, b, c, d, e, f
Quan et al <sup>8</sup> 2007	Ondansetron 4mg; Tropisetron 5mg	5	120/118	18-75 years, ASA: I-II; Elective surgery	Before induction of anesthesia	Yes or no	24	a, b, c
Ekinci et al <sup>9</sup> 2011	Ondansetron 4mg; Tropisetron 2.5mg	7	20/20	20-72 years, ASA: I-II; female; Total abdominal hysterectomy General Anesthesia	5 min after induction of anesthesia	Visual analog score 0-3	24	a, d, e, f
Sarvela et al <sup>10</sup> 2006	Ondansetron 8 mg; Tropisetron 5 mg	5	30/28	33±5 years; female; Elective cesarean section; Spinal-epidural anesthesia	5 min after delivery	Numerical rating score 0-10 >3	24	a, d
Scholz et al <sup>11</sup> 1998	Ondansetron 4 mg; Tropisetron 2 mg	6	271/296	18-75 years, ASA: I-III; abdominal and non-abdominal (ENT, eye, breast) surgery General anesthesia	3 min before induction of anesthesia	Yes or no	24	a, d, e
Naguib et al <sup>12</sup> 1996	Ondansetron 4 mg; Tropisetron 5 mg	5	29/25	21-68 years, ASA: I-II; Elective laparoscopic cholecystectomy; General anesthesia	10 min before induction of anesthesia	Yes or no	24	a
Koivuranta et al <sup>13</sup> 1999	Ondansetron 8 mg; Tropisetron 5 mg	6	45/43	≥18 years; ASA: I-III; Gynecological laparotomy; General anesthesia	At the end of surgery	Visual analog score 0-3	24	a, b, c, d, e, f
Wang et al <sup>14</sup> 2002	Ondansetron 8mg; Tropisetron 3mg	4	30/30	No mention Elective surgery; General anesthesia	At the end of surgery	Visual analog score 0-3	24	a, d
Wei et al <sup>15</sup> 1999	Ondansetron 4mg; Tropisetron 5mg	4	30/30	21-72 years, ASA: I-II; Elective abdominal surgery; General anesthesia	10 min before induction of anesthesia	Visual analog score 0-3	24	а, с
Paech et al <sup>16</sup> 2003	Ondansetron 4 mg; Tropisetron 2 mg	7	36/42	O: 48.3±12.2 years; T: 49.4±14.1 years; female; Major open abdominal gynecological surgery General anesthesia combined with epidural anesthesia	After induction of anesthesia	Visual analog score 0-3	24	b, c, d
Tsui et al <sup>17</sup> 1999	Ondansetron 4 mg; Tropisetron 5 mg	6	39/37	≤65 years; ASA: I-III; female; Gynecological laparotomy General anesthesia	Immediately before induction of anesthesia	Visual analog score 0-3	24	b, c, d
Geng et al <sup>18</sup> 2009	Ondansetron 8mg; Tropisetron 5mg	4	48/48	18-60 years, ASA: I-II; female; Gynecological laparotomy; General anesthesia	30 min before completion of surgery	Yes or no	24	b, c, d, f
Argiriadou et al <sup>19</sup> 2002	Ondansetron 4mg; Tropisetron 5mg	7	29/31	O: 43.9±13.6 years; T: 47.9±16.7 years; ASA: I-II; Elective laparoscopic cholecystectomy; General anesthesia	At anesthesia induction	Visual analog score 0-5	12	c, d, e

RCT: randomized controlled trial, ASA: American Society of Anesthesiologists, PONV: postoperative nausea and vomiting, O: Ondansetron, T: Tropisetron, a: The incidence of PONV, b: The incidence of PON, c: The incidence of POV, d: The incidence of antiemetic treatment, e: The incidence of headache, f: The incidence of dizziness




Figure 2 - Risk of bias summary.

A	Ondanse		Tropise			Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events		Weight	M-H, Fixed, 95% C		M-H, Fixed, 95% Cl	
Aydin2019	35	55	34	55	7.9%	1.08 [0.50, 2.34]		_	
Jokela2002	41	60	35	60	7.1%	1.54 [0.73, 3.26]			
Quan2007	36	120	37	118	16.7%	0.94 [0.54, 1.63]		-	
Ekinci2011	7	20	9	20	3.7%	0.66 [0.18, 2.35]			
Sarvela2006	7	30	3	28	1.5%	2.54 [0.59, 10.99]		<u> </u>	
Scholz1998	98	271	109	296	42.5%	0.97 [0.69, 1.37]			
Naguib1996	10	29	13	25	5.8%	0.49 [0.16, 1.45]			
Koivuranta1999	17	45	21	43	8.5%	0.64 [0.27, 1.49]			
Wang2002	14	30	5	30	1.7%	4.38 [1.32, 14.50]			
Wei1999	9	30	10	30	4.5%	0.86 [0.29, 2.55]			
Total (95% CI)		690		705	100.0%	1.02 [0.82, 1.28]		+	
Total events	274		276						
Heterogeneity: Chi <sup>2</sup> =	12.01, df =	9 (P = 0	).21);  ² =	25%			0.01	0.1 1 10	100
Test for overall effect:	Z = 0.20 (P	9 = 0.84)	)				0.01	Ondansetron Tropisetron	100
В			_						
	Ondanse		Tropise			Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events		Weight	M-H, Fixed, 95% C		M-H, Fixed, 95% Cl	
Aydin2019	35	55	31	55	13.1%	1.35 [0.63, 2.91]			
Jokela2002	39	60	38	60	15.5%	1.08 [0.51, 2.27]			
Quan2007	27	120	30	118	27.3%	0.85 [0.47, 1.55]			
Koivuranta1999	16	45	21	43	16.1%	0.58 [0.25, 1.36]			
Paech2003	24	36	30	42	10.8%	0.80 [0.31, 2.10]			
Tsui1999	27	39	21	37	7.7%	1.71 [0.67, 4.39]			
Geng2009	9	48	10	48	9.5%	0.88 [0.32, 2.40]			
Total (95% CI)		403		403	100.0%	0.97 [0.72, 1.31]			
Total events	177		181						
Heterogeneity: Chi2 =	4.00. df = 6	(P = 0.6	68): l <sup>2</sup> = 0	%			<b>—</b>		
Test for overall effect:							0.01	0.1 1 10	100
	- 0.10 (i	0.00)						Ondansetron Tropisetron	
С	Ondanse		Tropise			Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total		M-H. Fixed, 95% C	I		
Study or Subgroup Aydin2019	Events 8	Total 55	Events 9	Total 55	11.8%	M-H. Fixed, 95% C 0.87 [0.31, 2.45]	1	Odds Ratio	
Study or Subgroup Aydin2019 Jokela2002	Events 8 40	<u>Total</u> 55 60	Events 9 26	<u>Total</u> 55 60	11.8% 13.3%	M-H, Fixed, 95% C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49]		Odds Ratio	
Study or Subgroup Aydin2019 Jokela2002 Quan2007	Events 8 40 12	Total 55 60 120	Events 9 26 16	Total 55 60 118	11.8% 13.3% 22.4%	M-H. Fixed, 95% C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49] 0.71 [0.32, 1.57]	1	Odds Ratio	
Study or Subgroup Aydin2019 Jokela2002 Quan2007 Koivuranta1999	Events 8 40 12 6	Total 55 60 120 45	Events 9 26 16 6	Total 55 60 118 43	11.8% 13.3% 22.4% 8.2%	M-H. Fixed, 95% C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49] 0.71 [0.32, 1.57] 0.95 [0.28, 3.21]	I	Odds Ratio	
Study or Subgroup Aydin2019 Jokela2002 Quan2007 Koivuranta1999 Wei1999	Events 8 40 12 6 6	Total 55 60 120 45 30	Events 9 26 16 6 5	Total 55 60 118 43 30	11.8% 13.3% 22.4% 8.2% 6.2%	M-H. Fixed, 95% C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49] 0.71 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 4.64]	I	Odds Ratio	
Study or Subgroup Aydin2019 Jokela2002 Quan2007 Koivuranta1999 Wei1999 Paech2003	Events 8 40 12 6 6 6 27	Total 55 60 120 45 30 36	Events 9 26 16 6 5 24	Total 55 60 118 43 30 42	11.8% 13.3% 22.4% 8.2% 6.2% 8.5%	M-H, Fixed, 95% C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49] 0.71 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 4.64] 2.25 [0.85, 5.94]	<u> </u>	Odds Ratio	
Study or Subgroup Aydin2019 Jokela2002 Quan2007 Koivuranta1999 Wei1999 Paech2003 Tsui1999	Events 8 40 12 6 6 6 27 16	Total 55 60 120 45 30 36 39	Events 9 26 16 6 5 24 7	Total 55 60 118 43 30 42 37	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5%	M-H. Fixed, 95% C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49] 0.71 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 4.64] 2.25 [0.85, 5.94] 2.98 [1.05, 8.44]	<u> </u>	Odds Ratio	
Study or Subgroup Aydin2019 Jokela2002 Quan2007 Koivuranta1999 Wei1999 Paech2003 Tsui1999 Geng2009	Events 8 40 12 6 6 6 27 16 22	Total 55 60 120 45 30 36 39 48	Events 9 26 16 6 5 24 7 23	Total 55 60 118 43 30 42 37 48	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5% 19.2%	M-H. Fixed, 95% C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49] 0.71 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 4.64] 2.25 [0.85, 5.94] 2.98 [1.05, 8.44] 0.92 [0.41, 2.05]	1	Odds Ratio	
Study or Subgroup Aydin2019 Jokela2002 Quan2007 Koivuranta1999 Wei1999 Paech2003 Tsui1999	Events 8 40 12 6 6 6 27 16	Total 55 60 120 45 30 36 39	Events 9 26 16 6 5 24 7	Total 55 60 118 43 30 42 37	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5%	M-H. Fixed, 95% C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49] 0.71 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 4.64] 2.25 [0.85, 5.94] 2.98 [1.05, 8.44]	1	Odds Ratio	
Study or Subgroup Aydin2019 Jokela2002 Quan2007 Koivuranta1999 Wei1999 Paech2003 Tsui1999 Geng2009	Events 8 40 12 6 6 6 27 16 22	Total 55 60 120 45 30 36 39 48	Events 9 26 16 6 5 24 7 23	Total 55 60 118 43 30 42 37 48 31	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5% 19.2%	M-H. Fixed, 95% C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49] 0.71 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 4.64] 2.25 [0.85, 5.94] 2.98 [1.05, 8.44] 0.92 [0.41, 2.05]	I	Odds Ratio	
Study or Subgroup Aydin2019 Jokela2002 Quan2007 Koivuranta1999 Wei1999 Paech2003 Tsui1999 Geng2009 Argiriadou2002	Events 8 40 12 6 6 6 27 16 22	Total 55 60 120 45 30 36 39 48 29	Events 9 26 16 6 5 24 7 23	Total 55 60 118 43 30 42 37 48 31	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5% 19.2% 3.9%	M+H, Fixed, 95% C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49] 0.71 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 4.64] 2.25 [0.85, 5.94] 2.98 [1.05, 8.44] 0.92 [0.41, 2.05] 1.49 [0.30, 7.33]	1	Odds Ratio	
Study or Subgroup           Aydin2019           Jokela2002           Quan2007           Koivuranta1999           Wei1999           Paech2003           Tsui1999           Geng2009           Argiriadou2002           Total (95% Cl)	Events 8 40 12 6 6 6 27 16 22 4 4	Total           55           60           120           45           30           36           39           48           29           462	Events 9 26 16 6 5 24 7 23 3 119	Total 55 60 118 43 30 42 37 48 31 464	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5% 19.2% 3.9%	M+H, Fixed, 95% C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49] 0.71 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 4.64] 2.25 [0.85, 5.94] 2.98 [1.05, 8.44] 0.92 [0.41, 2.05] 1.49 [0.30, 7.33]		Odds Ratio	
Tudy or Subgroup           Aydin2019           Jokela2002           Quan2007           Koivuranta 1999           Wei1999           Paech2003           Tsui1999           Geng2009           Argiriadou2002           Total (95% CI)           Total events	Events 8 40 12 6 6 6 27 16 22 4 141 10.78, df =	Total 55 60 120 45 30 36 39 48 29 462 8 (P = 0	Events 9 26 16 6 5 24 7 23 3 3 119 0.21); I <sup>2</sup> =	Total 55 60 118 43 30 42 37 48 31 464	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5% 19.2% 3.9%	M+H, Fixed, 95% C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49] 0.71 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 4.64] 2.25 [0.85, 5.94] 2.98 [1.05, 8.44] 0.92 [0.41, 2.05] 1.49 [0.30, 7.33]	0.01	Odds Ratio	100
Study or Subgroup Aydin(2019 Jokela2002 Quar2007 Koivuranta1999 Paech2003 Tsui1999 Geng2009 Argiradou2002 Total (95% CI) Total events Heterogeneity: Chi <sup>a</sup> =	Events 8 40 12 6 6 6 27 16 22 4 141 10.78, df =	Total 55 60 120 45 30 36 39 48 29 462 8 (P = 0 9 = 0.04)	Events 9 26 16 6 5 24 7 23 3 3 119 0.21); I <sup>2</sup> =	Total 55 60 118 43 30 42 37 48 31 464 26%	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5% 19.2% 3.9%	M+H, Fixed, 95% C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49] 0.71 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 4.64] 2.25 [0.85, 5.94] 2.98 [1.05, 8.44] 0.92 [0.41, 2.05] 1.49 [0.30, 7.33]		Odds Ratio	100
Study or Subgroup Aydin2019 Jokela2002 Quar2007 Koivuranta1999 Wei1999 Paech2003 Tsui1999 Geng2009 Argiradou2002 Total (95% CI) Total events Heterogeneily: Chi <sup>9</sup> = Test for overall effect:	Events 8 40 12 6 6 27 16 22 4 141 10.78, df = Z = 2.02 (P	Total 55 60 120 45 30 36 39 48 29 462 8 (P = 0 9 = 0.04)	Events 9 266 16 6 5 24 7 23 3 119 0.21);  ² =	Total           55           60           118           43           30           42           37           48           31           464           26%           ttron	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5% 19.2% 3.9%	M-H. Fixed. 95% C 0.87 [0.31, 245] 2.62 [1.25, 5.49] 0.77 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 64] 2.25 [0.85, 5.84] 2.98 [1.05, 8.44] 0.92 [0.41, 2.05] 1.49 [0.30, 7.33] 1.39 [1.01, 1.90]	0.01	Odds Ratio M-H, Fixed, 95% Cl	100
Study or Subgroup           Aydin2019           Jokela2002           Quan2007           Koivranta 1999           Paech2003           Tsu1999           Geng2009           Arginiadou2002           Total (95% CI)           D	Events 8 40 12 6 6 27 16 22 4 141 10.78, df = Z = 2.02 (P Ondanse	Total 55 60 120 45 30 36 39 48 29 462 8 (P = 0 2 = 0.04) etron	Events 9 266 6 5 24 7 23 3 119 0.21); I <sup>2</sup> =	Total           55           60           118           43           30           42           37           48           31           464           26%           ttron	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5% 19.2% 3.9%	M-H. Fixed, <u>95%</u> C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49] 0.71 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 4.64] 2.25 [0.85, 5.94] 2.98 [1.05, 8.44] 0.92 [0.41, 2.05] 1.49 [0.30, 7.33] 1.39 [1.01, 1.90] Odds Ratio	0.01	Odds Ratio	100
Study or Subgroup Aydin2019 Jokela2002 Quar2007 Koivranta1999 We1999 Paech2003 Tsu1999 Geng2009 Arginadou2002 Total (95% CI) Total events Heterogeneily: Chi <sup>p</sup> = Test for overall effect: D Study or Subgroup	Events 8 40 12 6 6 27 16 22 4 141 10.78, df = Z = 2.02 (P Ondanse Events	Total           55           60           120           45           30           36           39           48           29           462           8 (P = 0           e = 0.04)           etron           Total	Events 9 26 16 6 5 24 7 23 3 119 0.21); I <sup>2</sup> = 7 Tropise Events	Total           55           60           118           43           30           42           37           48           31           464           26%           ttron           Total	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5% 19.2% 3.9% 100.0%	M-H. Fixed, <u>95%</u> C 0.87 (0.31, 2.45) 2.62 (1.25, 5.49) 2.62 (1.25, 5.49) 0.71 (0.32, 1.57) 0.95 (0.28, 3.21) 1.25 (0.34, 4.64) 2.25 (0.86, 5.94) 2.96 (1.05, 8.44) 0.92 (0.41, 2.05) 1.49 (0.30, 7.33) 1.49 [1.01, 1.90] Odds Ratio M-H. Fixed, <u>95%</u> C	0.01	Odds Ratio	100
Study or Subgroup Aydin2019 Jokela2002 Quar2007 Koivuranta1999 Paech2003 Tsu11999 Geng2009 Argiriadou2002 Total (95% CI) Total events Heterogeneity: Chi* = Total reverts Heterogeneity: Chi* = Study or Subgroup Aydin2019	Events 8 40 12 6 6 27 16 22 4 141 10.78, df = Z = 2.02 (P Ondanso Events 27	Total           55           60           120           45           30           36           39           48           29           462           8 (P = 0.04)           etron           Total           55	Events 9 26 16 6 5 24 7 23 3 119 0.21); I <sup>2</sup> = ) Tropise Events 32	Total           55           60           118           43           30           42           37           48           31           464           26%           ttron           Total           55	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5% 19.2% 3.9% 100.0% Weight 14.1%	M-H. Fixed, <u>95% C</u> 0.87 [0.31, 245] 2.62 [1.25, 5.49] 0.77 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 6.4] 2.25 [0.85, 5.94] 2.25 [0.85, 5.94] 2.25 [0.85, 5.94] 2.25 [0.85, 5.94] 2.25 [0.85, 5.94] 2.25 [0.35, 5.94] 3.25 [0.35, 5.95] 3.25 [0.35,	0.01	Odds Ratio	
Study or Subgroup           Aydin2019           Jokela2002           Quan2007           Koivranta 1999           Paech2003           Tsu11999           Ceng2009           Arginiadou2002           Total (95% CI)           Jotela2003           Aydin2019           Jokela20202	Events 8 40 12 6 6 7 7 16 22 4 141 10.78, df = Z = 2.02 (P Ondanse Events 27 38	Total           55           60           120           45           30           36           39           48           29           462           8 (P = 0.04)           etron           Total           55           60	Events 9 26 16 6 5 24 7 23 3 119 0.21); I <sup>2</sup> = Tropise Events 32 30	Total           55           60           118           43           30           42           37           48           31           464           226%           ttron           55           60	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5% 19.2% 3.9% 100.0% Weight 14.1% 9.5%	M-H. Fixed, <u>95%</u> C 0.87 [0.31, 2.45] 2.62 [1.25, 5.49] 0.71 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 4.64] 2.25 [0.85, 5.94] 2.26 [0.85, 5.94] 2.26 [0.85, 5.94] 2.92 [0.14, 2.05] 1.49 [0.30, 7.33] 1.39 [1.01, 1.90] Odds Ratio M-H. Fixed, <u>95%</u> C 0.69 [0.33, 1.47] 1.73 [0.83, 3.58]	0.01	Odds Ratio	
Study or Subgroup           Aydin2019           Jokela2002           Quar2007           Quar2007           Roivranta1999           Wei1999           Paech2003           Taui1999           Geng2009           Arginadou2002           Total (95% CI)           Total events           Heterogeneily: Chi <sup>p</sup> =           Test for overall effect:           D           Study or Subgroup           Aydin2019           Jokela2002           Ekinc2011	Events 8 40 12 6 6 27 16 22 4 141 10.78, df = Z = 2.02 (P Ondanse Events 27 38 3 3	Total           55         60           120         45           30         36           39         48           29         462           8 (P = 0         -           0.04)         -           etron         -           Total         55           60         20	Events 9 26 16 5 24 7 23 3 119 0.21); I <sup>2</sup> = Tropise Events 30 5	Total           55           60           118           43           30           42           37           48           31           464           26%           ttron           55           60           20%           20%	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 19.2% 3.9% 100.0% Weight 14.1% 9.5% 3.7%	M-H. Fixed, 95% C 0.87 (0.31, 2.45) 2.62 (1.25, 5.49) 2.62 (1.25, 5.49) 0.71 (0.32, 1.57) 0.95 (0.28, 3.21) 1.25 (0.34, 4.64) 2.25 (0.85, 5.94) 2.96 (1.05, 8.44) 0.92 (0.41, 2.05) 1.49 (0.30, 7.33) 1.39 [1.01, 1.90] Odds Ratio M-H. Fixed, 95% C 0.66 (0.33, 1.47) 1.73 (0.83, 3.58) 0.53 (0.11, 2.60)	0.01	Odds Ratio	100
Study or Subgroup           Aydin2019           Jokela2002           Quar2007           Koivuranta1999           Paech2003           Tsui1999           Paech2003           Tsui1999           Argiriadouz002           Total (95% CI)           Total events           Heterogeneity: Chi* =           Study or Subgroup           Aydin2019           Jokela2002           Ekind2019           Sudvard Subgroup           Aydin2019           Jokela2002           Ekind2011           Sarvela2006	Events         8           40         12           6         6           27         16           22         4           141         10.78, df =           Z = 2.02 (P         Ondanse           Ondanse         27           38         3           4         3	Total           55         60           120         45           30         36           39         48           29         462           8 (P = 0         0.04)           etron         Total           55         60           20         3.040	Events. 9 26 16 6 5 24 4 7 23 3 3 119 9 2.21); I <sup>2</sup> = Tropises 32 30 5 1	Total           55         60           118         43           30         42           37         48           31         464           26%         tron           Total         55           60         20           28         20	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5% 19.2% 3.9% 100.0% Weight 14.1% 9.5% 0.8%	M-H. Fixed, <u>95%</u> C 0.87 (0.31, 2.45) 2.62 (1.25, 5.49) 0.71 (0.32, 1.57) 0.95 (0.28, 3.21) 1.25 (0.34, 4.64) 2.26 (0.85, 5.94) 2.26 (0.85, 5.94) 2.92 (0.41, 2.05) 1.49 (0.30, 7.33) 1.39 [1.01, 1.90] Odds Ratio M-H. Fixed, <u>95%</u> C 0.69 (0.33, 1.47) 1.73 (0.83, 3.58) 0.53 (0.11, 2.60) 4.15 (0.43, 3.967) 0.88 (0.60, 1.33)	0.01	Odds Ratio	100
Study or Subgroup           Aydin2019           Jokela2002           Quar2007           Quar2007           Roivranta1999           Wei1999           Paech2003           Taui1999           Geng2009           Arginadou2002           Total (95% CI)           Total events           Heterogeneily: Chi <sup>p</sup> =           Test for overall effect:           D           Study or Subgroup           Aydin2019           Jokela2002           Exinc2011           Sarvela2006           Scholz1998           Koivuranta1999	Events 8 40 12 6 6 27 16 6 22 4 141 10.78, df = Z = 2.02 (P Ondanse Events 38 3 4 6 14	Total           55           60           120           45           30           36           39           48           29           462           8 (P = 0.04)           etron           Total           55           60           20           300           271	Events. 9 9 266 166 6 5 244 7 23 3 119 120;  ² = Events 32 300 5 1 1 7 7 7 7 7 7 7 7 7 7 7 7 7	Total           55           60           118           43           30           42           37           48           31           464           26%           tron           Total           55           60           20%           210           28           296           43	11.8% 13.3% 22.4% 8.2% 6.2% 6.5% 6.5% 19.2% 3.9% 100.0% Weight 14.1% 9.5% 3.7% 0.8% 10.4%	M-H. Fixed, 95% C 0.87 (0.31, 2.45) 2.62 (1.25, 5.49) 2.62 (1.25, 5.49) 1.25 (0.24, 3.21) 1.25 (0.34, 4.64) 2.25 (0.85, 5.94) 2.29 (1.05, 8.44) 0.92 (0.41, 2.05) 1.49 (0.30, 7.33) 1.39 [1.01, 1.90] Odds Ratio M-H. Fixed, 95% C 0.68 (0.33, 1.47) 1.73 (0.83, 3.68) 0.53 (0.11, 2.60) 4.15 (0.43, 3.967) 0.89 (0.60, 1.33) 0.68 (0.29, 1.66]	0.01	Odds Ratio	100
Study or Subgroup           Aydin2019           Jokela2002           Quar2007           Koivaranta 1999           Paech2003           Tsui 1999           Paech2003           Tsui 1999           Argiriadouz002           Total (95% CI)           Total events           Heterogeneity: Chi* =           D           Study or Subgroup           Aydin2019           Jokela2002           Ekino2011           Sarvela2006           Schürz1998           Koivuranta1999           Paech2003	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\frac{\text{Total}}{55}$ 60 120 45 30 36 39 48 29 462 8 (P = 0 - 0.44) etron Total 55 60 0 20 30 271 45	Events 9 9 26 6 5 5 24 7 7 23 3 3 119 9 2.21); P = 9 7 Tropisse 32 30 0 5 1 6 7 7 7 7 7 7 7 3 3	Total           55           60           118           43           30           42           37           48           31           464           26%           tron           Total           55           60           226%           tron           28           296           43           42	11.8% 13.3% 22.4% 8.2% 6.5% 6.5% 19.2% 3.9% 100.0% Weight 14.1% 9.5% 3.7% 0.8% 0.4% 6.1%	M-H, Fixed, 95% C 0.87 [0.31, 245] 2.62 [1.25, 5.49] 0.77 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 6.44] 0.92 [0.41, 2.05] 1.49 [0.30, 7.33] 1.39 [1.01, 1.90] Odds Ratio M-H, Fixed, 95% C 0.69 [0.33, 1.47] 1.73 [0.83, 3.58] 0.53 [0.11, 2.60] 4.15 [0.43, 39.67] 0.89 [0.60, 1.33] 0.89 [0.60, 1.33] 0.89 [0.69, 1.68] 1.59 [0.68, 4.04]	0.01	Odds Ratio	100
Study or Subgroup           Aydin2019           Jokela2002           Quan2007           Koivranta1999           Paech2003           Tsui1999           Paech2003           Tsui1999           Ceng2009           Arginiadou2002           Total (95% CI)           Total events           Heterogeneity: Chi* =           Test for overall effect:           D           Study or Subgroup           Aydin2019           Jokela2002           Ekino2011           Sarvela2006           Scholz1998           Koivuranta1999           Paech2003           Tsui1999	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	$\begin{array}{c} \hline {\rm Total} \\ 55 \\ 60 \\ 120 \\ 45 \\ 30 \\ 39 \\ 48 \\ 29 \\ 462 \\ 8 \\ (P=0.04) \\ etron \\ \hline {\rm Total} \\ 55 \\ 60 \\ 20 \\ 30 \\ 271 \\ 45 \\ 66 \\ 39 \\ \end{array}$	Events 9 9 26 6 5 24 7 7 23 3 3 119 9 2.21); I <sup>2</sup> = Events 32 30 5 5 1 167 77 717 33	Total           55           60           118           43           30           42           37           48           31           464           26%           ttron           Total           55           60           20%           208           296           43           42           37	11.8% 13.3% 22.4% 8.2% 6.5% 6.5% 19.2% 3.9% 100.0% Weight 14.1% 9.5% 3.7% 0.8% 44.1% 10.4% 5.5% 3.5%	M-H. Fixed, <u>95%</u> C 0.87 (0.31, 2.45) 2.62 (1.25, 5.49) 0.71 (0.32, 1.57) 0.95 (0.28, 3.21) 1.25 (0.34, 4.64) 2.26 (0.85, 5.94) 2.92 (0.41, 2.05) 1.49 (0.30, 7.33) 1.39 [1.01, 1.90] Odds Ratio M-H. Fixed, <u>95%</u> C 0.66 (0.33, 1.47) 1.73 (0.83, 3.58) 0.53 (0.11, 2.60) 4.15 (0.43, 3.967) 0.88 (0.60, 1.33) 0.68 (0.29, 1.66) 1.59 (0.63, 0.44) 1.65 (0.49, 5.60)	0.01	Odds Ratio	
Study or Subgroup           Aydin2019           Jokela2002           Quar2007           Koivaranta 1999           Paech2003           Tsui 1999           Paech2003           Tsui 1999           Argiriadouz002           Total (95% CI)           Total events           Heterogeneity: Chi* =           D           Study or Subgroup           Aydin2019           Jokela2002           Ekino2011           Sarvela2006           Schürz1998           Koivuranta1999           Paech2003	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	Total           55           60           120           45           30           36           39           48           29           462           8 (P = 0           0 = 0.04)           etron           Total           55           60           20           30           271           45           36	Events 9 9 26 6 5 5 24 7 7 23 3 3 119 9 2.21); P = 9 7 Tropisse 32 30 0 5 1 6 7 7 7 7 7 7 7 3 3	Total           55           60           118           43           30           42           37           48           31           464           26%           tron           Total           55           60           226%           tron           28           296           43           42	11.8% 13.3% 22.4% 8.2% 6.5% 6.5% 19.2% 3.9% 100.0% Weight 14.1% 9.5% 3.7% 0.8% 0.4% 6.1%	M-H, Fixed, 95% C 0.87 [0.31, 245] 2.62 [1.25, 5.49] 0.77 [0.32, 1.57] 0.95 [0.28, 3.21] 1.25 [0.34, 6.44] 0.92 [0.41, 2.05] 1.49 [0.30, 7.33] 1.39 [1.01, 1.90] Odds Ratio M-H, Fixed, 95% C 0.69 [0.33, 1.47] 1.73 [0.83, 3.58] 0.53 [0.11, 2.60] 4.15 [0.43, 39.67] 0.89 [0.60, 1.33] 0.89 [0.60, 1.33] 0.89 [0.69, 1.68] 1.59 [0.68, 4.04]	0.01	Odds Ratio	100
Study or Subgroup Aydin2019 Jokela2002 Quan2007 Koiviarnata1999 Wei1999 Paech2003 Tsui1999 Geng2009 Arginiadou2002 Total events Heterogeneity: Chi <sup>2</sup> = Children Study or Subgroup Aydin2019 Jokela2002 Ekino2011 Sarvla2006 Scholz1998 Koiviarnata1999 Paech2003 Tsui1999 Geng2009 Arginadou2002	Events         8           8         8           400         12           12         6           6         6           7         16           22         2           4         1           10.78, df =         2           27         27           33         3           4         4           15         8           8         6	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	Events 9 9 26 5 5 24 7 7 23 3 3 119 9 2.21); l <sup>2</sup> = 9 2.21); l <sup>2</sup> = 10,221; l <sup>2</sup>	Total           55           60           118           43           30           42           37           48           311           464           26%           tron           Total           55           60           20%           tron           28%           43           464           55           60           20%           43           42           37           48           31	11.8% 13.3% 22.4% 6.2% 6.2% 6.5% 19.2% 3.9% 100.0% Weight 14.1% 9.5% 0.8% 44.1% 0.4% 3.7% 0.8% 4.4% 3.2%	M-H. Fixed, 95% C 0.87 (0.31, 2-45) 2.62 (1.25, 5.49) 0.71 (0.32, 1.57) 0.95 (0.28, 3.21) 1.25 (0.34, 4.64) 2.25 (0.85, 5.94) 2.98 (1.05, 8.44) 0.92 (0.41, 2.05) 1.49 (0.30, 7.33) 1.39 [1.01, 1.90] Odds Ratio M-H. Fixed, 95% C 0.68 (0.33, 1.47) 1.73 (0.83, 3.58) 0.53 (0.11, 2.60) 4.15 (0.43, 3.67) 0.89 (0.60, 1.33) 0.69 (0.29, 1.66) 1.59 (0.63, 0.44) 1.65 (0.49, 5.60) 1.00 (0.30, 3.55) 1.65 (0.46, 5.55)	0.01	Odds Ratio	
Study or Subgroup           Aydin2019           Aydin2019           Jokela2002           Quar2007           Koivranta1999           Wei1999           Geng2009           Argiriadou2002           Total (95% CI)           Total events           Heterogeneily: Chi <sup>p</sup> =           D           Study or Subgroup           Aydica2002           Exinc2011           Sarvela2006           Scholz1998           Koivuranta1999           Pach2003           Tsui1999           Geng2009           Argiriadou2002	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	Total           55           60           120           45           30           36           9           462           8 (P = 0           0.44)           55           60           20           462           8 (P = 0.04)           etron           Total           55           60           20           300           2711           45           36           369           48	Events 9 9 266 6 6 5 24 4 7 7 23 3 3 119 9 2.21); l <sup>2</sup> = 9 7 Tropise 5 32 300 5 5 1 67 77 13 3 5 6 6 5 5 5 6 6 5 5 9 24 6 7 23 3 7 26 7 23 7 23 7 26 7 26 7 23 7 23	Total           55           60           118           43           30           42           37           48           311           464           26%           tron           Total           55           60           20%           tron           28%           43           464           55           60           20%           43           42           37           48           31	11.8% 13.3% 22.4% 8.2% 6.2% 8.5% 6.5% 19.2% 3.9% 100.0% Weight 14.1% 9.5% 3.7% 100.0%	M-H. Fixed, 95% C 0.87 (0.31, 2-45) 2.62 (1.25, 5.49) 2.62 (1.25, 5.49) 2.62 (1.25, 5.49) 1.25 (0.34, 1.24) 2.25 (0.85, 5.94) 2.25 (0.85, 5.94) 2.25 (0.85, 5.94) 2.25 (0.14, 2.45) 0.42 (0.41, 2.05) 1.43 (0.30, 7.33) 1.39 [1.01, 1.90] 0.043 Ratio M-H. Fixed, 95% C 0.68 (0.33, 1.47) 1.73 (0.83, 3.58) 0.53 (0.11, 2.60) 4.15 (0.43, 3.66) 0.53 (0.11, 2.60) 4.15 (0.43, 3.66) 1.59 (0.63, 4.04) 1.65 (0.49, 5.60) 1.00 (0.30, 3.35)	0.01	Odds Ratio	
Study or Subgroup           Aydin2019           Jokela2002           Quan2007           Koivaranta 1999           Paech2003           Tsu1999           Paech2003           Tsu1999           Geng2009           Argiriadou2002           Total (95% CI)           Jokela2002           Study or Subgroup           Aydin2019           Sarvela2006           Scholz 1998           Koivranta 1999           Paech2003           Tsu1999           Geng2009           Argiriadou2002           Total (95% CI)           Total (95% CI)	$\begin{tabular}{c} \hline Events & 8 \\ 8 & 40 \\ 12 & 2 \\ 6 & 6 \\ 6 & 77 \\ 16 & 6 \\ 22 & 2 \\ 4 & 141 \\ 10.78, df = 2 \\ 22 & 202 \\ r \\ r \\ 0 \\ r \\ 38 & 3 \\ 4 & 56 \\ 6 & 6 \\ 14 & 15 \\ 8 & 8 \\ 6 & 7 \\ 7 \\ 178 & 178 \\ end{tabular}$	Total           55           60           120           48           29           462           8 (P = 0           0 = 0.04)           etron           Total           55           60           20           462           8 (P = 0.04)           etron           Total           55           60           20.04)           etron           Total           55           60           20.02           300           2711           45           36           39           48           29           633	Events 9 9 266 6 5 5 24 7 7 23 3 3 119 9 2.21); l <sup>2</sup> = 7 Tropises Events 32 30 0 5 1 1 7 7 7 3 3 2 8 2 6 6 5 5 8 2 4 4 7 7 23 3 3 7 26 6 6 6 6 5 24 4 7 7 23 3 3 7 26 6 7 24 7 26 7 26 7 26 7 24 7 26 7 26	Total           55           60           118           43           30           42           37           48           31           464           26%           ttron           Total           55           60           20%           444           26%           ttron           Total           55           60           20           28           296           43           43           43           43           43           43           43           43           43           464           33           660	11.8% 13.3% 22.4% 6.2% 6.2% 6.5% 19.2% 3.9% 100.0% Weight 14.1% 9.5% 0.8% 44.1% 0.4% 3.7% 0.8% 4.4% 3.2%	M-H. Fixed, 95% C 0.87 (0.31, 2-45) 2.62 (1.25, 5.49) 0.71 (0.32, 1.57) 0.95 (0.28, 3.21) 1.25 (0.34, 4.64) 2.25 (0.85, 5.94) 2.98 (1.05, 8.44) 0.92 (0.41, 2.05) 1.49 (0.30, 7.33) 1.39 [1.01, 1.90] Odds Ratio M-H. Fixed, 95% C 0.68 (0.33, 1.47) 1.73 (0.83, 3.58) 0.53 (0.11, 2.60) 4.15 (0.43, 3.67) 0.89 (0.60, 1.33) 0.69 (0.29, 1.66) 1.59 (0.63, 0.44) 1.65 (0.49, 5.60) 1.00 (0.30, 3.55) 1.65 (0.46, 5.55)	0.01	Odds Ratio	
Study or Subgroup           Aydin2019           Aydin2019           Jokela2002           Quar2007           Koivranta1999           Wei1999           Geng2009           Argiriadou2002           Total (95% CI)           Total events           Heterogeneily: Chi <sup>p</sup> =           D           Study or Subgroup           Aydica2002           Exinc2011           Sarvela2006           Scholz1998           Koivuranta1999           Pach2003           Tsui1999           Geng2009           Argiriadou2002	Events         8           8         40           12         6           6         6           27         16           12         2           4         141           11         10.78, df = 1           2.02 (F)         2.02 (F)           2.1 2.02 (F)         2.02 (F)           3.3 3         3           4         56           14         15           8         6           7         7           178         8.8.88, df = 9	$\begin{array}{c} \hline {\rm Total} \\ 55 \\ 60 \\ 120 \\ 120 \\ 30 \\ 30 \\ 36 \\ 39 \\ 48 \\ 29 \\ 462 \\ e = 0.04 \\ e \\ ron \\ \hline {\rm Total} \\ 55 \\ 60 \\ 20 \\ 00 \\ 271 \\ 45 \\ 36 \\ 39 \\ 9 \\ 48 \\ 29 \\ 633 \\ 0 \\ ({\rm P}=0 \\ 100 \\$	Events 9 9 266 6 5 24 4 7 23 3 3 119 9 2.21); P = 9 2 230 0 5 5 1 1 67 77 13 3 5 6 6 5 5 119 9 26 8 24 9 26 6 6 7 23 3 3 3 7 23 3 3 7 26 6 7 23 3 3 7 26 6 7 23 3 3 7 23 3 7 26 7 23 3 7 26 7 23 3 7 26 7 23 3 7 23 3 7 23 3 7 24 7 23 3 7 24 7 23 3 7 24 7 25 7 24 7 23 3 7 24 7 25 7 24 7 23 3 7 7 23 3 7 7 23 3 7 7 23 3 7 7 24 7 23 3 7 7 24 7 23 3 7 7 24 7 25 7 24 7 25 7 24 7 23 7 25 7 24 7 24 7 25 7 24 7 25 7 24 7 25 7 24 7 25 7 24 7 29 7 29 7 29 7 29 7 20 7 20 7 20 7 21 7 21 7 22 3 22 7 20 7 21 7 21 7 22 3 22 3 22 3 2 7 23 3 2 2 3 2 3 2 3	Total           55           60           118           43           30           42           37           48           31           464           26%           ttron           Total           55           60           20%           444           26%           ttron           Total           55           60           20           28           296           43           43           43           43           43           43           43           43           43           464           33           660	11.8% 13.3% 22.4% 6.2% 6.2% 6.5% 19.2% 3.9% 100.0% Weight 14.1% 9.5% 0.8% 44.1% 0.4% 3.7% 0.8% 4.6.1% 3.5%	M-H. Fixed, 95% C 0.87 (0.31, 2-45) 2.62 (1.25, 5.49) 0.71 (0.32, 1.57) 0.95 (0.28, 3.21) 1.25 (0.34, 4.64) 2.25 (0.85, 5.94) 2.98 (1.05, 8.44) 0.92 (0.41, 2.05) 1.49 (0.30, 7.33) 1.39 [1.01, 1.90] Odds Ratio M-H. Fixed, 95% C 0.68 (0.33, 1.47) 1.73 (0.83, 3.58) 0.53 (0.11, 2.60) 4.15 (0.43, 3.67) 0.89 (0.60, 1.33) 0.69 (0.29, 1.66) 1.59 (0.63, 0.44) 1.65 (0.49, 5.60) 1.00 (0.30, 3.55) 1.65 (0.46, 5.55)	0.01	Odds Ratio	

Figure 3 - Forest plot comparing between ondansetron and tropisetron: A) postoperative nausea and vomiting; B) postoperative nausea; C) postoperative vomiting; D) antiemetic treatment.

As shown in Figure 3, 10 studies involving 1395 patients reported the incidence of PONV. The effect of ondansetron and tropisetron was equal in preventing PONV (OR: 1.02; 95% CI: 0.82-1.28; p=0.84; I<sup>2</sup>=25%) (Figure 3A).<sup>6-15</sup>

Postoperative nausea (PON) was assessed in 7 studies including 806 patients.<sup>6-8,16-18</sup> Meanwhile, postoperative vomiting (POV) was reported in 9 studies including

926 patients.<sup>6-8,13,15-19</sup> This meta-analysis indicated no difference in PON between ondansetron and tropisetron (OR: 0.97; 95% CI: 0.72–1.31; p=0.85; I<sup>2</sup>=0%) (**Figure 3B**). Ondansetron was 39% less effective than tropisetron in preventing POV (OR: 1.39; 95% CI: 1.01-1.90; p=0.04; I<sup>2</sup>=26%) (**Figure 3C**).

Antiemetic treatment. Antiemetic treatment was reported in 10 studies including 1293

Ondansetron	versus	tropisetron	for	PONV		Wang et a	l
-------------	--------	-------------	-----	------	--	-----------	---




Figure 4 - Forest plot of comparison of the side effects experienced by patients receiving ondansetron and tropisetron treatment: A) headache and B) dizziness.

patients.<sup>6,7,9-11,13,16-19</sup> The difference in antiemetic treatment was not statistically significant between ondansetron and tropisetron (OR: 1.03; 95% CI: 0.80-1.33; p=0.81; I<sup>2</sup> = 0%) (Figure 3D).

*Complications*. Headache was evaluated in 6 studies involving 985 patients.<sup>6,7,9,11,13,19</sup> As displayed in **Figure 4A**, ondansetron compared to tropisetron tended to have higher incidence of headache; however, it wasn't statistically significant (OR: 1.58; 95% CI: 1.00-2.50; p=0.05;  $I^2=23\%$ ). On the other hand, dizziness was evaluated in 4 studies involving 344 patients.<sup>7,9,13,18</sup> As shown in **Figure 4B**, ondansetron had 103% higher incidence of dizziness than that with tropisetron (OR: 2.03; 95% CI: 1.20-3.43; p=0.008;  $I^2=34\%$ ).

**Publication bias.** The funnel plot of PONV was asymmetrical. However, Egger test did not reveal significant difference in PONV (p=0.501).

**Discussion.** Previous systematic review has shown that 5-HT3 receptor antagonists could prevent PONV.<sup>20</sup> The mechanism may be that they can block vagal nerves which trigger the emetic reflex.<sup>21</sup> Ondansetron is the original member of this class with a short elimination

half-life, and its effect is confirmed in many studies of different patient populations. Tropisetron is also a potent 5-HT3 receptor antagonist with longer elimination half-life than that of ondansetron. It is produced by systematic methyl substitution of the serotonin molecules.<sup>22</sup> It is still a matter of significant interest to compare the efficacy and side-effect profiles of the short-acting ondansetron and the relatively long-acting tropisetron prophylactically given to patients of both genders undergoing surgery.

The present meta-analysis indicated that tropisetron was more effective than ondansetron in preventing POV, and prophylactic ondansetron and tropisetron had similar incidence of PONV, incidence of PON, and antiemetic efficacy in adults.

We note a difference in the half-life time of ondansetron (T1/2 = 3.2 hours) and tropisetron (T1/2 = 7.3-8 hours), which is probably related to the lower percentage of patients who experienced POV in the tropisetron group.<sup>23</sup> It indicates that prophylactic tropisetron can provide a more long-standing antiemetic coverage after surgery. However, tropisetron does not reduce the incidence of PONV and PON, and

requirement for antiemetic treatment, as compared to that with ondansetron.

Furthermore, tropisetron causes fewer side effects than ondansetron. Compared with ondansetron, tropisetron can decrease the incidence of dizziness. Additionally, tropisetron tends to increase the incidence of headache; however, this difference was not statistically significant. If more RCTs are included and more patients are involved, tropisetron may be shown to be more effective. Nonetheless, we were able to demonstrate in this meta-analysis that tropisetron can more effectively prevent POV with a lower incidence of dizziness than ondansetron.

Several potential limitations associated with these results should be mentioned. First, 2 of the included RCTs had relatively small sample sizes, which might influence the credibility of the conclusion. Second, there were some clinical differences between the included studies: dosages and the administration routes of the study drugs in the included RCTs vary, which may affect the reliability of pooling effects. Finally, the optimal dosages of ondansetron and tropisetron were the remaining question, which need further attention.

In conclusion, tropisetron is superior to ondansetron in preventing POV. It is 39% more effective than ondansetron in preventing POV with a lower incidence of dizziness.

**Acknowledgment.** We would like to thank Editage (www.editage.cn) for English language editing.

## References

- 1. Kovac AL. Updates in the management of postoperative nausea and vomiting. *Adv Anesth* 2018; 36: 81-97.
- 2. Matsuura H, Inoue S, Kawaguchi M. The risk of postoperative nausea and vomiting between surgical patients received propofol and sevoflurane anesthesia: a matched study. *Acta Anaesthesiol Taiwan* 2016; 54: 114-120.
- Yokoi A, Mihara T, Ka K, Goto T. Comparative efficacy of ramosetron and ondansetron in preventing postoperative nausea and vomiting: an updated systematic review and meta-analysis with trial sequential analysis. *PLoS One* 2017; 12: e0186006.
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration. *BMJ* 2011; 343: d5928.
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports on randomized clinical trials: is blinding necessary? *Controlled Clinical Trials* 1996; 17: 1-12.
- Aydin A, Kaçmaz M, Boyaci A. Comparison of ondansetron, tropisetron, and palonosetron for the prevention of postoperative nausea and vomiting after middle ear surgery. *Curr Ther Res Clin Exp* 2019; 91: 17-21.

- Jokela R, Koivuranta M, Kangas-Saarela T, Purhonen S, Alahuhta S. Oral ondansetron, tropisetron or metoclopramide to prevent postoperative nausea and vomiting: a comparison in high-risk patients undergoing thyroid or parathyroid surgery. *Acta Anaesthesiol Scand* 2002; 46: 519-524.
- 8. Quan X, Ye TH, Zhu B. [A randomized double-blind study of prevention of postoperative nausea and vomiting with ondansetron, tropisetron, or granisetron in patients undergoing general anesthesia]. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 2007; 29: 107-110. Chinese
- 9. Ekinci O, Malat I, Işıtmangil G, Aydın N. A randomized comparison of droperidol, metoclopramide, tropisetron, and ondansetron for the prevention of postoperative nausea and vomiting. *Gynecol Obstet Invest* 2011; 71: 59-65.
- Sarvela PJ, Halonen PM, Soikkeli AI, Kainu JP, Korttila KT. Ondansetron and tropisetron do not prevent intraspinal morphine and fentanyl induced pruritus in elective cesarean delivery. *Acta Anaesthesiol Scand* 2006; 50: 239-244.
- Scholz J, Hennes HJ, Steinfath M, Färber L, Schweiger C, Dick W, et al. Tropisetron or ondansetron compared with placebo for prevention of postoperative nausea and vomiting. *Eur J Anaesthesiol* 1998; 15: 676-685.
- 12. Naguib M, el Bakry AK, Khoshim MH, Channa AB, el Gammal M, el Gammal K, et al. Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo. *Can J Anaesth* 1996; 43: 226-231.
- Koivuranta M, Ala-Kokko TI, Jokela R, Ranta P. Comparison of ondansetron and tropisetron combined with droperidol for the prevention of emesis in women with a history of post-operative nausea and vomiting. *Eur J Anaesthesiol* 1999; 16: 390-395.
- 14. Wang C, Xu N, Xiong LZ, Liu HF, Yang XY, Lu ZH, et al. [Dexamethasone enhances the effect of tropisetron and ondansetron against nausea and vomiting against nausea and vomiting after patient-controlled analgesia]. *Di Yi Jun Yi Da Xue Xue Bao* 2002; 22: 159-161. Chinese.
- Zhao W, Li C, Jia N. Prevention of postoperative nausea and vomiting with tropisetron or ondansetron in patients undergoing general anesthesia. *Journal of China-Japan Friendship Hospital* 1999; 13: 154-156.
- Paech MJ, Rucklidge MWM, Banks SL, Gurrin LC, Orlikowski CEP, Pavy TJG. The efficacy and cost-effectiveness of prophylactic 5-hydroxytryptamine3 receptor antagonists: Tropisetron, Ondansetron and Dolasetron. *Anaesth Intensive Care* 2003; 31: 11-17.
- Tsui SL, Ng KF, Wong LC, Tang GW, Pun TC, Yang JC. Prevention of postoperative nausea and vomiting in gynaecological laparotomies: a comparison of tropisetron and ondansetron. *Anaesth Intensive Care* 1999; 27: 471-476.
- Geng ZY, Wang DX, Liu YH. Prevention of postoperative nausea and vomiting in patients undergoing gynecological laparoscopy: a comparison of tropisetron and ondansetron. *Chinese Journal of New Drugs* 2009; 18: 2316-2319.
- Argiriadou H, Papaziogas B, Pavlidis T, Parlapani A, Georgiou M, Papagiannopoulou P, et al. Tropisetron vs ondansetron for prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomized double-blind, placebo-controlled study. *Surg Endosc* 2002; 16: 1087-1090.

- 20. Sridharan K, Sivaramakrishnan G. Drugs for preventing post-operative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: Network meta-analysis of randomized clinical trials and trial sequential analysis. *Int J Surg* 2019; 69: 1-12.
- Juza R, Vlcek P, Mezeiova E, Musilek K, Soukup O, Korabecny J. Recent advances with 5-HT(3) modulators for neuropsychiatric and gastrointestinal disorders. *Med Res Rev* 2020; 40: 1593-1678.
- 22. Yang Y, Zhang L. A narrative review of tropisetron and palonosetron for the control of chemotherapy-induced nausea and vomiting. *Chin Clin Oncol* 2020; 9: 17.
- Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. *Clin Pharmacol Ther.* 2017; 102: 213-218.